Loading...
HSChapter 30
U.S. imports of alkaloid-containing medicaments (not in dosage form, nesoi) (HS 300349) totaled $985K in April 2026, traded with 5 countries.
Alkaloid-Containing Medicaments (Not in Dosage Form, NESOI) imports of $985K in April 2026 ran 35% below the year-to-date monthly average of $1.5M.
Last updated: April 2026 dataCovering alkaloid-based pharmaceutical preparations not elsewhere specified and not put up in measured doses, tariff line 3003490000 captures a broad range of plant-derived and synthetic alkaloid APIs — from opioid precursors to antimalarial compounds — that fall outside the pseudoephedrine-specific line. India leads US imports under this heading, followed by Taiwan, the United Kingdom, Denmark, and Canada, a supplier mix that reflects both generic API manufacturing capacity and originator pharmaceutical operations. Depending on the specific alkaloid, DEA scheduling requirements may apply in addition to standard FDA import procedures, making pre-import regulatory screening essential. Importers should verify whether the alkaloid in question is a controlled substance or listed chemical before shipment.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
The importer should cross-reference the alkaloid's CAS number against DEA's schedules of controlled substances and list of listed chemicals. If the substance appears on either list, DEA registration and, where applicable, import quota compliance are required before the shipment can enter. FDA registration of the foreign establishment is a separate, parallel requirement.
Customs and FDA will look at the commercial invoice, certificate of analysis, and packaging to confirm the product is a bulk API or intermediate rather than a packaged, measured-dose product. Key indicators include labeling in kilograms rather than unit doses, absence of patient-facing labeling, and a drug master file reference rather than an NDA/ANDA number. Mischaracterizing a finished product as bulk API to avoid dosage-form classification is a compliance risk.
Supplier Network
Get discovered by U.S. importers searching for HS 300349 — Alkaloid-Containing Medicaments (Not in Dosage Form, NESOI). Be the first supplier listed.
Monthly import values over time
| Country | Imports | Exports | Balance |
|---|---|---|---|
| INDIA | $657K | $5K | -$653K |
| COLOMBIA | -- | $439K | +$439K |
| UNITED KINGDOM | $327K | -- | -$327K |
| ITALY | -- | $50K | +$50K |
| SAUDI ARABIA | -- | $45K | +$45K |
HS10 import codes under this HS6 parent. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Import Value | Effective Tariff % |
|---|---|---|---|
| 3003490000 | OTHER MEDICAMENTS CONTAINING ALKALOIDS/DERIVAT | $985K | -- |
OTHER MEDICAMENTS CONTAINING ALKALOIDS/DERIVAT
HS10 export codes under this HS6 parent. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3003490000 | OTHER MEDICAMENTS CONTAINING ALKALOIDS/DERIVAT | $538K |
OTHER MEDICAMENTS CONTAINING ALKALOIDS/DERIVAT
29.7K kg
MEDICAMENTS NESOI, MEASURED DOSES, RETAIL PK NESOI
HS 300490
IMMUNOLOGICAL PRODUCTS, IN MEASURED DOESE/RTL SALE
HS 300215
VACCINES FOR HUMAN MEDICINE
HS 300241
HORMONES ETC. (NO ANTIBIOTICS CONTAINED) DOSAGE FM
HS 300439
ANTISERA AND OTHER BLOOD FRACTIONS
HS 300212
IMMUNOLOGICAL PRODUCTS, MIXED, NOT IN MSRED DOSES
HS 300214
| State | Imports | Exports | Balance |
|---|---|---|---|
| Pennsylvania | $657K | -- | -$657K |
| Florida | -- | $439K | +$439K |
| New York | $151K | -- | -$151K |
| Port | Imports | Exports | Balance |
|---|---|---|---|
| JFK INTERNATIONAL AIRPORT, NY | $954K | -- | -$954K |
| PORT EVERGLADES, FL | -- | $439K | +$439K |
| CHICAGO, IL | $30K | $50K | +$19K |